Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shanna Suderman

Physician Assistant Wichita, KS Physician Assistant

NPI 1588704076 CMS profile 10591063

9300 E 29Th St N Ste 310, Wichita, KS 67226

Open in the dashboard

General payments

$12,668

744 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shanna Suderman of Wichita, KS is reported in the CMS Open Payments database as having received $12,668 across 744 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,694 158
2024 General $3,073 156
2023 General $2,313 134
2022 General $2,659 165
2021 General $1,929 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shanna Suderman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Shanna Suderman were reported at $2,694. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Shanna Suderman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,929 $132 $37–$438 $132
2022 $2,659 $155 $48–$522 $149
2023 $2,313 $167 $52–$557 $160
2024 $3,073 $178 $55–$600 $164
2025 $2,694 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,951 184 payments
  2. Janssen Biotech, Inc. $2,096 108 payments
  3. Novartis Pharmaceuticals Corporation $1,278 94 payments
  4. E.R. Squibb & Sons, L.L.C. $1,206 64 payments
  5. Amgen Inc. $963 45 payments
  6. Lilly USA, LLC $800 54 payments
  7. Dermavant Sciences, Inc. $539 31 payments
  8. Regeneron Healthcare Solutions, Inc. $498 24 payments
  9. Genzyme Corporation $461 21 payments
  10. LEO Pharma Inc. $458 26 payments
  11. Other $1,418 93 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,183 738 payments
  2. Education $486 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,878 90 payments
  2. SKYRIZI $1,258 92 payments
  3. SOTYKTU $1,201 63 payments
  4. RINVOQ $1,050 49 payments
  5. Otezla $963 45 payments
  6. COSENTYX $761 48 payments
  7. TALTZ $577 50 payments
  8. VTAMA $556 34 payments
  9. HUMIRA $498 26 payments
  10. DUPIXENT $476 21 payments
  11. Other $4,952 329 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

920

Median for Physician Assistant: 241

Drug cost

$669,568

Median for Physician Assistant: $4,110

Branded share of claims

13%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 22 $347,183
Dupixent Pen Dupilumab Brand 40 $154,937
Humira(Cf) Adalimumab Brand 13 $104,447
Vtama Tapinarof Brand 16 $23,004
Eucrisa Crisaborole Brand 13 $16,585
Clobetasol Propionate Generic 147 $8,317
Halobetasol Propionate Generic 19 $2,791
Doxycycline Hyclate Generic 59 $1,615
Ketoconazole Generic 96 $1,417
Acitretin Generic 13 $1,403

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$205,466

Of which drugs: $15,671

Medicare patients

1,267

Average age 75

Services billed

5,920

720 women, 547 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 41%
Ischemic heart disease 27%
Diabetes 23%
Chronic kidney disease 21%
Depression 19%
Atrial fibrillation 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 19 51 $15,607
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 42 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
$584 — —
TREMFYA
$436 — —
RINVOQ
$381 — —
COSENTYX
$314 — —
SKYRIZI
$283 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

744 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record